Trends in healthcare expenditures and resource utilization among a nationally representative population with opioids in the United States: a serial cross-sectional study, 2008 to 2017.

Autor: Bounthavong M; U.S. Department of Veterans Affairs, Veterans Health Administration, Washington, DC, USA. mbounthavong@health.ucsd.edu.; UCSD Skaggs School of Pharmacy & Pharmaceutical Sciences, 9500 Gilman Drive, MC 0657, La Jolla, CA, 92093-0657, USA. mbounthavong@health.ucsd.edu., Suh K; University of Pittsburgh School of Pharmacy, Pittsburgh, USA., Li M; University of Texas MD Anderson Cancer Center, Houston, USA., Spoutz PM; U.S. Department of Veterans Affairs, Veterans Health Administration, Washington, DC, USA., Stottlemyer BA; University of Pittsburgh School of Pharmacy, Pittsburgh, USA., Sepassi A; UCSD Skaggs School of Pharmacy & Pharmaceutical Sciences, 9500 Gilman Drive, MC 0657, La Jolla, CA, 92093-0657, USA.
Jazyk: angličtina
Zdroj: Substance abuse treatment, prevention, and policy [Subst Abuse Treat Prev Policy] 2021 Oct 20; Vol. 16 (1), pp. 80. Date of Electronic Publication: 2021 Oct 20.
DOI: 10.1186/s13011-021-00415-5
Abstrakt: Background: Previous reports on healthcare costs and expenditures associated with populations prescribed an opioid primarily focused on populations who chronically use opioids or have opioid use disorder. However, studies that characterize the healthcare and expenditures costs among the wider number of people prescribed opioids in a nationally representative population are unavailable. We sought to characterize the healthcare costs and expenditures associated with a population prescribed an opioid in the U.S. from 2008 to 2017.
Methods: A serial cross-sectional design was used to compare the economic burden of adult household respondents who were prescribed and not prescribed an opioid using pooled data from the Medical Expenditure Panel Survey (MEPS) between 2008 and 2017. Respondents with an opioid prescription were matched to respondents without an opioid prescription using propensity score match methods with survey weights. Two-part generalized linear models were used to estimate the survey-weighted annual healthcare expenditures and resource utilization adjusting for multiple covariates. Additionally, 10-year trend comparisons between the groups were performed. Costs were adjusted to 2019 US dollars.
Results: There was a weighted total of 31,696,671 respondents with an opioid and 31,536,639 respondents without an opioid after propensity score matching. The sample had a mean (SD) age of 50.63 years (18.03), 58.9% females, and 81.6% Whites. Total annual economic burden among RPOs was $524 billion. Annual total expenditures per respondent with and without an opioid were $16,542 and $7067, respectively (P < 0.001). Similarly, adjusted prescription, outpatient, emergency department, and inpatient expenditures were significantly higher for respondents with an opioid compared to respondents without an opioid. Average annual increases in expenditures were significantly greater among respondents with an opioid compared to respondents without an opioid for total (+$185; 95% CI: $37-$334) and prescription (+$78; 95% CI: $28-$128) expenditures. There were no differences in the average annual trends for outpatient, emergency department, and inpatient expenditures between respondents with and without an opioid.
Conclusions: Respondents with an opioid prescription had higher healthcare expenditures and resource utilization compared to respondents without an opioid prescription from 2008 to 2017. Specifically, significant annual increases were observed for total and prescription expenditures. Additionally, 10-year trends in total and prescription expenditures were higher among respondents with an opioid than respondents without an opioid.
(© 2021. The Author(s).)
Databáze: MEDLINE
Externí odkaz: